European Union antitrust officials are investigating whether drug companies, including Pfizer, AstraZeneca PLC, Sanofi-Aventis SA and GlaxoSmithKline PLC, have tried to keep generic or rival drugs off the market. "Without new pharmaceuticals, the quality of some medical treatments will stagnate; without generic products, the cost of some medical treatments will remain high," EU antitrust chief Neelie Kroes said.

Related Summaries